On January 14, 2013, Dr. Christopher McGuigan was appointed as a Director of TrovaGene, Inc. to serve until the next election of directors by the stockholders and until the election and qualification of his successor. Dr. McGuigan was nominated for the position by the Corporate Governance/Nominating Committee of the Board of Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.22 USD | -4.72% |
|
-9.39% | +50.00% |
05-02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.00% | 99.29M | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- CRDF Stock
- News Cardiff Oncology, Inc.
- TrovaGene, Inc. Appoints Christopher Mcguigan as Director